Omalizumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4687 publications
Three years treatment with HDM allergen immunotherapy, omalizumab, or combination therapy in allergic asthma: clinical outcomes and biomarkers.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: April 15, 2026
Preventing Food Anaphylaxis.
Journal: Immunology and allergy clinics of North America
Published: April 03, 2026
Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC
Journal: Laryngo- rhino- otologie
Published: April 02, 2026
Control Status of Chronic Rhinosinusitis in Severe Asthma Patients Receiving Biologics: A Real-World Cross-Sectional Study.
Journal: The Annals of otology, rhinology, and laryngology
Published: April 02, 2026
Fab-Fc and Fab-Fab interactions of variable strength and valency contribute to the high concentration viscosity of IgG1 antibodies.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 24, 2026
Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies.
Journal: Expert opinion on biological therapy
Published: March 24, 2026
What to do when your adult patient with severe asthma does not respond to a biologic.
Journal: Allergy and asthma proceedings
Published: March 17, 2026
Acute and Chronic Urticaria: Evaluation and Treatment.
Journal: American family physician
Published: March 16, 2026
Efficacy and safety of biologics in children and adolescents with eosinophilic asthma: A systematic review and meta-Analysis.
Journal: Asian Pacific journal of allergy and immunology
Published: March 15, 2026
Biologics in severe asthma: from precision phenotyping to clinical remission.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: March 14, 2026
Depemokimab (Exdensur) for severe eosinophilic asthma.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026
Drug survival and safety in chronic urticaria: comparative analysis of omalizumab and antihistamines.
Journal: Cutaneous and ocular toxicology
Published: March 06, 2026
Last Updated: 04/28/2026